Home Cart Sign in  
Chemical Structure| 84504-69-8 Chemical Structure| 84504-69-8

Structure of Irsogladine maleate
CAS No.: 84504-69-8

Chemical Structure| 84504-69-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.

Synonyms: MN1695; Dicloguamine maleate; Irsogladine (maleate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Irsogladine maleate

CAS No. :84504-69-8
Formula : C13H11Cl2N5O4
M.W : 372.16
SMILES Code : ClC1=C(C2=NC(N)=NC(N)=N2)C=C(Cl)C=C1.OC(/C=C\C(O)=O)=O
Synonyms :
MN1695; Dicloguamine maleate; Irsogladine (maleate)
MDL No. :MFCD00873566
InChI Key :PJLVTVAIERNDEQ-BTJKTKAUSA-N
Pubchem ID :5282435

Safety of Irsogladine maleate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312-P330-P501

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03509831 Gastritis Phase 1 Active, not recruiting April 2018 Korea, Republic of ... More >> Kukje Pharm Seongnam-si, Korea, Republic of Less <<
NCT02581696 Peptic Ulcer Phase 1 Completed - Korea, Republic of ... More >> The Catholic University of Korea, Seoul St.Mary's Hospital Seoul, Korea, Republic of Less <<
NCT02759224 Gastric Ulcer Phase 1 Completed - Korea, Republic of ... More >> The Catholic University of Korea, Seoul St.Mary's Hospital Seoul, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.44mL

2.69mL

1.34mL

26.87mL

5.37mL

2.69mL

References

[1]Nozaki S, Maeda M, et al. Inhibition of breast cancer regrowth and pulmonary metastasis in nude mice by anti-gastric ulcer agent, irsogladine. Breast Cancer Res Treat. 2004 Feb;83(3):195-9.

[2]Kyoi T, Kitazawa S, et al. Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats. J Pharmacol Sci. 2004 Jul;95(3):321-8.

[3]Ren CJ, Ueda F, Roses DF, Harris MN, Mignatti P, Rifkin DB, Shapiro RL. Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. J Surg Res. 1998 Jul 1;77(2):126-31

[4]Kawasaki Y, Tsuchida A, Sasaki T, Yamasaki S, Kuwada Y, Murakami M, Chayama K. Irsogladine malate up-regulates gap junctional intercellular communication between pancreatic cancer cells via PKA pathway. Pancreas. 2002 Nov;25(4):373-7

[5]Nomura M, Kamata M, Kojima H, Hayashi K, Sawada S. Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis. Ann Oncol. 2013 Apr;24(4):1062-6

[6]Fujita T, Kishimoto A, Shiba H, Hayashida K, Kajiya M, Uchida Y, Matsuda S, Takeda K, Ouhara K, Kawaguchi H, Abiko Y, Kurihara H. Irsogladine maleate regulates neutrophil migration and E-cadherin expression in gingival epithelium stimulated by Aggregatibacter actinomycetemcomitans. Biochem Pharmacol. 2010 May 15;79(10):1496-505

[7]Shim KN, Kim JI, Kim N, Kim SG, Jo YJ, Hong SJ, Shin JE, Kim GH, Park KS, Choi SC, Kwon JG, Kim JH, Kim HJ, Kim JW. The efficacy and safety of irsogladine maleate in nonsteroidal anti-inflammatory drug or aspirin-induced peptic ulcer and gastritis. Korean J Intern Med. 2019 Sep;34(5):1008-1021

 

Historical Records

Categories